The University of Utah is entering a collaboration agreement with Pregna International, a leading contraceptive manufacturer based in Mumbai, India, to commercialize a “molecular condom” and other anti-HIV and contraceptive technologies in that country. The molecular condom comes in the form of a gel composed of molecules that are liquid at room temperature but, when applied in the vagina, spread and turn into a gel that coats the tissue. When the gel comes into contact with semen during intercourse, it releases anti-HIV drugs. The technology is still several years from commercialization, but researchers see the “smart” microbicide delivery system as a way for women to gain power by protecting themselves from HIV, which is spread primarily through heterosexual contact in India and many other countries. The agreement is part of a larger commercialization plan between the university and four India-based companies, including Pregna. Go to: Medical News and Health News Blog and University of Utah

Write a comment